Stock in News Spotlight: VolitionRx Limited (NYSE AMERICAN:VNRX)

VolitionRx Limited (NYSE AMERICAN:VNRX) changed -1.61% to recent value of $4.89. The stock transacted 73566 shares during most recent day however it has an average volume of 133.93K shares. It spotted trading -28.51% off 52-week high price. On the other end, the stock has been noted 131.75% away from the low price over the last 52-weeks.

On Jan. 10, 2020, VolitionRx Limited (NYSE AMERICAN:VNRX) released the closing of the acquisition of the epigenetic reagent company Octamer GmbH (Octamer) by its subsidiary Belgian Volition SPRL for approximately $725,000, consisting of cash and shares of restricted common stock of Volition. This strategic acquisition helps secure the supply of one of the key components of Volition’s Nu.Q(TM) tests, the recombinant nucleosome used as the calibrant.

Volition also announced the receipt of additional non-dilutive funding in the form of a $550,000 (Euro 500,000) unsecured loan from Namur Invest to assist with the Octamer acquisition. This takes the total non-dilutive funding provided by the Namur Regional Government and associated agencies to over $7 million to-date.

Commenting on the announcement Cameron Reynolds, Chief Executive Officer of Volition said, This acquisition means that we will be working with one of the world’s leading nucleosome experts, Dr. Adrian Schomburg. Not only will this deal secure the supply of a wide range of our key components, but it will also facilitate the transfer of know-how and expertise so that we can develop the capability to manufacture recombinant nucleosomes in Volition’s laboratory. This deal enhances our goal of becoming one of the world’s leading epigenetics companies. I would like to thank Namur Invest for their continued support of our many projects.

Its earnings per share (EPS) expected to touch remained -2.50% for this year .

The company has 39.98M of outstanding shares and 22.85M shares were floated in the market. According to the most recent quarter its current ratio was 6.3 that represents company’s ability to meet its current financial obligations. The price moved ahead of 3.23% from the mean of 20 days, -2.85% from mean of 50 days SMA and performed 17.90% from mean of 200 days price. Company’s performance for the week was 1.87%, 7.47% for month and YTD performance remained 3.16%.

Leave a Reply

Your email address will not be published. Required fields are marked *